Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers
1+ hour, 24+ min ago (450+ words) The LATA study pitted Cabenuva against a triple therapy in teenagers aged 12 to 19 with HIV in Africa. ViiV Healthcare’s two-monthly HIV drug has demonstrated superiority over daily oral medication in a Phase III trial conducted in four African countries. The…...
Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority
1+ week, 1+ day ago (613+ words) If approved, ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market as patients rely on once-daily options. Gilead and MSD (Merck & Co) have released data for their two-drug combination human immunodeficiency virus (HIV) therapy, islatravir-lenacapavir…...